Therapeutics Pipeline
Explore our innovative development pipeline for gastrointestinal cancers.
TriAx/Bispecific Antibody Platform
Drug
Discovery
Preclinical
Phase 1
Phase 2
ARB202
Learn moreCDH17 / CD3 TCE
ARB203
Learn moreBispecific TCE
Undisclosed
Learn moreTrispecific TCE
Undisclosed
Learn moreTrispecific TCE
Antibody Drug Conjugate (ADC)
Drug
Discovery
Preclinical
Phase 1
Phase 2
ARB102A
FDA-approved drug
ARB103A
Photocaged drug
Undisclosed
Bispecific ADC
Undisclosed
Bispecific ADC
Advanced Cell Therapy (CAR)
Drug
Discovery
Preclinical
Phase 1
Phase 2
ARB001
CAR-T
ARB011
CAR-NK/T
Diagnostics Pipeline
Explore our innovative development pipeline for gastrointestinal cancers.
Antibody Drug Conjugate (ADC)
Platform
Intended Use
Prototyping / Optimization
Manufacturing
Clinical Studies
Launch
CDH17 - IHC Test
GI cancer diagnostics
CDH17 - Blood Test
CRC screening / surveillance
CDH17 - POCT
Point-of-Care Test
Join our research
Explore our pipeline
Discover our groundbreaking immunotherapy platforms for gastrointestinal cancers.